What you need to know about paxlovid: the first oral antiviral for COVID-19 approved in Canada Pfizer’s Paxlovid expected to overshadow Merck’s molnupiravir, with higher efficacy in preventing hospitalization/death in high-risk outpatients with mild/moderate COVID-19. Low rate of false-positive rapid antigen test results in Canadian workplacesStudy investigates the incidence of false-positives in a large sample of SARS-CoV-2 rapid antigen tests used to screen asymptomatic workers throughout Canada. 2021 CTS guideline update: Diagnosis and management of asthma in preschoolers, children and adults Guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Breakthrough COVID-19 infection rates higher among those with immune dysfunction But vaccination still offers protection, study finds How should chronic cough be assessed and managed? Canadian review highlights recommended investigations, current management options and new treatments under study for chronic cough Text messaging service for monitoring COVID-19 at home reduces mortality Study finds a 64% relative reduction in the risk for death, and one life saved for every 400 patients enrolled in the remote monitoring service. Research roundup: COVID ICU practice guidelines, tools for coping with patient deaths, history of respiratory disease Here are three research papers that caught our eye this week. Moderna makes submission to Health Canada for COVID-19 vax for kids from 6 to 11 Studies for Spikevax for kids even younger are ongoing. FAQ sheet for parents on COVID-19 vaccinations for kids from UWaterloo School of Pharmacy The University of Waterloo School of Pharmacy has compiled an answer sheet to frequently asked questions in anticipation of COVID-19 vaccinations being approved for younger kids. Pfizer says COVID-19 pill cut hospital, death risk by 90% First Previous 17 18 19 20 21 Next Last
